Key facts
- This page summarizes Daniel Janney's Form 4 filing for Esperion Therapeutics, Inc. (ESPR).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 28 May 2021, 16:16.
Daniel Janney - 27 May 2021 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)
- Reporting relationship
- Director
- Issuer ticker
- ESPR
- Reported as of
- 27 May 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 May 2021, 16:16:49 UTC
- Prior SEC filing
- 14 Oct 2021
- Next SEC filing
- 02 Jul 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard B. Bartram, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel Janney filed Form 4 for Esperion Therapeutics, Inc. (ESPR) on 28 May 2021.
Change
- Previous filing in this sequence was filed on 14 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ESPR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +12,376
- Change %
- +112%
- Price
- $0.000000
- Shares after
- 23,449
- Date
- 27 May 2021
- Ownership
- Direct
- Footnotes
- F1
ESPR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 24,565
- Date
- 27 May 2021
- Ownership
- By Alta Bioequities, L.P.
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares vest in full on the earlier of (i) May 27, 2022 and (ii) the Issuer's next annual meeting of stockholders following May 27, 2021.
Footnote F2
On February 28, 2018, Alta Partners VIII, L.P. ("APVIII") distributed 624,564 shares of Common Stock on a pro rata basis, for no additional consideration, to its partners, which distribution was exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9 and Rule 16a-13. Alta Bioequities, L.P. ("Alta Bioequities") received 24,565 of these shares. Alta Bioequities Management, LLC is the general partner of Alta Bioequities L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC and may be deemed to have voting and investment power over the shares owned by Alta Bioequities, L.P.